Gritstone Oncology initiated with a Buy at Berenberg. Berenberg analyst Shanshan Xu initiated Gritstone Oncology with a Buy rating and $30 price target, stating that Gritstone’s neoantigen platform may represent the “best-in-class” algorithm for identifying bona fide neoantigens. The company also has a vaccine “prime-and-boost” platform that may also be differentiated, Xu noted.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.